Send to

Choose Destination
Oncoimmunology. 2012 Dec 1;1(9):1640-1642.

Anticancer activity of cardiac glycosides: At the frontier between cell-autonomous and immunological effects.

Author information

INSERM; U848; Villejuif, France ; Institut Gustave Roussy; Villejuif, France ; Université Paris Sud/Paris XI; Le Kremlin Bicêtre, France.


Retrospective clinical data indicate that cardiac glycosides (CGs), notably digoxin, prolong the survival of carcinoma patients treated with conventional chemotherapy. CGs are known to influence the immune response at multiple levels. In addition, recent results suggest that CGs trigger the immunogenic demise of cancer cells, an effect that most likely contributes to their clinical anticancer activity.

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center